AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term, we believe ...

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...

Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

PARP Inhibitor Market is projected to expand substantially, surpassing USD 16,153.50 million by 2034 at a CAGR of 8.70%.

Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...

The global psoriatic arthritis (PsA) treatment market is poised for remarkable expansion, with an anticipated valuation of ...

Abbvie Inc. failed to defeat a proposed class action by a Chicago-area technician who says he and other workers were ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $193.51 which represents a decrease of $-0.32 or -0.17% from the prior close of $193.83. The stock opened at $192.95 and touched a low of $191.

AbbVie Inc. closed $6.44 short of its 52-week high ($199.95), which the company achieved on September 3rd.

The next frame shows the Ubrelvy logo in the backstage hallway along with a blue lit path. Frames six to seven then show Serena Williams walking down the blue lit path, no longer exhibiting migraine ...

With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the ...